Compare ZDGE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZDGE | NRXS |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2M | 46.3M |
| IPO Year | N/A | N/A |
| Metric | ZDGE | NRXS |
|---|---|---|
| Price | $3.28 | $5.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 68.3K | ★ 83.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.27 | $31.05 |
| Revenue Next Year | $5.76 | $146.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $1.33 |
| 52 Week High | $4.89 | $6.20 |
| Indicator | ZDGE | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 72.02 |
| Support Level | $3.02 | $4.50 |
| Resistance Level | $3.34 | $4.50 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 56.25 | 92.66 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).